Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer

MLA

K.L. Juliëtte Schmidt, et al. “Long-Term Immunity after BNT162b2 MRNA COVID-19 Vaccination in Pediatric Patients with Cancer.” EJC Paediatric Oncology, vol. 4, no. 100172-, Dec. 2024. EBSCOhost, https://doi.org/10.1016/j.ejcped.2024.100172.

APA

K.L. Juliëtte Schmidt, Noortje R. Severeijns, Noël M.M. Dautzenberg, Peter M. Hoogerbrugge, Caroline A. Lindemans, Stefan Nierkens, Gaby Smits, Rob S. van Binnendijk, Marta Fiocco, Louis J. Bont, & Wim J.E. Tissing. (2024). Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer. EJC Paediatric Oncology, 4(100172-). https://doi.org/10.1016/j.ejcped.2024.100172

Chicago

K.L. Juliëtte Schmidt, Noortje R. Severeijns, Noël M.M. Dautzenberg, Peter M. Hoogerbrugge, Caroline A. Lindemans, Stefan Nierkens, Gaby Smits, et al. 2024. “Long-Term Immunity after BNT162b2 MRNA COVID-19 Vaccination in Pediatric Patients with Cancer.” EJC Paediatric Oncology 4 (100172-). doi:10.1016/j.ejcped.2024.100172.